Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study ; volume:44 ; number:7 ; day:27 ; month:6 ; year:2024 ; pages:513-525 ; date:7.2024
Clinical drug investigation ; 44, Heft 7 (27.6.2024), 513-525, 7.2024
- Urheber
-
Mohan, M. V. T. Krishna
Prajapati, Arpitkumar
Kothari, Rushabh
Mandal, Srikrishna
Srikanth, Ranganatha Rao
Nagarkar, Rajnish
Khane, Shriram
Santa, Ayyagari
Dadke, Disha
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-024-01374-y
- URN
-
urn:nbn:de:101:1-2410072116278.986556104899
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mohan, M. V. T. Krishna
- Prajapati, Arpitkumar
- Kothari, Rushabh
- Mandal, Srikrishna
- Srikanth, Ranganatha Rao
- Nagarkar, Rajnish
- Khane, Shriram
- Santa, Ayyagari
- Dadke, Disha
- SpringerLink (Online service)
Ähnliche Objekte (12)
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
How We Treat HER2-Positive Metastatic Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
How We Treat HER2-Positive Metastatic Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
How We Treat HER2-Positive Metastatic Breast Cancer